Translokin (Cep57) interacts with cyclin D1 and prevents its nuclear accumulation in quiescent fibroblasts

Maria Ruiz-Miró1, Neus Colomina, Rita M H Fernández

  • 1Departament de Ciències Mèdiques Bàsiques, IRBLLEIDA, Universitat de Lleida, Montserrat Roig 2, 25008 Lleida, Catalonia, Spain.

Insights

Translokin (Tlk) regulates cyclin D1

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Cancer Research

Background:

  • Nuclear accumulation of cyclin D1 is linked to cancer development.
  • Control of cyclin D1 localization during cell cycle exit and quiescence is not well understood.

Purpose of the Study:

  • To investigate the role of translokin (Tlk) in regulating cyclin D1's nucleocytoplasmic distribution.
  • To understand Tlk's function in maintaining cellular quiescence.

Main Methods:

  • Investigated the interaction between translokin (Tlk) and cyclin D1.
  • Analyzed the effect of Tlk levels on cyclin D1 localization and pRB phosphorylation.
  • Studied the impact of Tlk on cell cycle progression.

Main Results:

  • Translokin (Tlk) interacts with cyclin D1 and controls its nuclear import.
  • Tlk downregulation leads to cyclin D1 nuclear accumulation and increased pRB phosphorylation in quiescent cells.
  • Tlk overexpression inhibits cyclin D1 nuclear accumulation, pRB phosphorylation, and S-phase entry in proliferating cells.

Conclusions:

  • Translokin (Tlk) acts as a negative regulator of cyclin D1 nuclear import.
  • Tlk plays a crucial role in maintaining cellular quiescence by preventing pRB inactivation.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...